Cannabidiol (CBD), as a non-addictive chemical, is the main component in the extract of medicinal plant Cannabis sativa. The cannabidiol provided for medical use, with significant anticonvulsant, anti-vomiting, anti-spasm, anti-anxiety, anti-insomnia, anti-inflammatory, antioxidant and sedative effects, is utilized to treat diseases such as epilepsy and Parkinson's disease. The cannabidiol provided for recreative use, with remarkable functions of refreshing, anti-fatigue and anti-aging, is used as an additive in food/beverages and cosmetics. On June 25th 2018, GW RESEARCH LTD in the United States developed an oral liquid preparation of high-purity cannabidiol extract, Epidiolex, for the treatment of Lennox-Gastaut syndrome (LGS) and seizures associated with Dravet syndrome (DS). By 2019, more than 50 countries have Ｄeclared CBD legal. In 2018, the global legal CBD product sale was about $12 billion; by 2025, the market is predicted to reach $50 billion. Currently, the production of cannabidiol mainly relies on traditional extraction method, of which the main disadvantage is the tediousness in operation and residue of impurities, such as tetrahydrocannabinol (THC). After years of cooperative development, Sichuan Aupone Pharmaceutical and the West China School of Pharmacy, Sichuan University have innovatively devised a new CBD industrialized synthetic process, which has prominent advantages than traditional extraction process in terms of product purity, cost, production capacity and regulatory compliance.